methyl 4-fluorobenzenecarbimidothioate hydroiodide | 354764-40-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-fluorobenzenecarbimidothioate hydroiodide
• 英文别名: Methyl 4-fluorobenzenecarboximidothioate;hydroiodide
• CAS: 354764-40-2
• 化学式: C₈H₈FNS*HI
• 分子量: 297.135
• InChiKey: OHDNUOXLHPNNSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.13
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  49.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 4-fluorobenzenecarbimidothioate hydroiodide 以 乙醇 为溶剂， 反应 64.0h， 生成 (1R,3R)-3-[3-(4-fluorophenyl)-1H-1,2,4-triazol-5-yl]-1-(oxan-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
  参考文献：
  名称：

  SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists

  摘要：

  MK-4256, a tetrahydro-beta-carboline sstr3 antagonist, was discontinued due to a cardiovascular (CV) adverse effect observed in dogs. Additional investigations revealed that the CV liability (QTc prolongation) was caused by the hERG off-target activity of MK-4256 and was not due to sstr3 antagonism. In this Letter, we describe our extensive SAR effort at the C3 position of the tetrahydro-beta-carboline structure. This effort resulted in identification of 5-fluoro-pyridin-2-yl as the optimal substituent on the imidazole ring to balance sstr3 activity and the hERG off-target liability. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.02.022
• 作为产物：
  描述：

  4-氟硫代苄胺 、 碘甲烷 以 丙酮 为溶剂， 反应 16.0h， 生成 methyl 4-fluorobenzenecarbimidothioate hydroiodide
  参考文献：
  名称：

  SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists

  摘要：

  MK-4256, a tetrahydro-beta-carboline sstr3 antagonist, was discontinued due to a cardiovascular (CV) adverse effect observed in dogs. Additional investigations revealed that the CV liability (QTc prolongation) was caused by the hERG off-target activity of MK-4256 and was not due to sstr3 antagonism. In this Letter, we describe our extensive SAR effort at the C3 position of the tetrahydro-beta-carboline structure. This effort resulted in identification of 5-fluoro-pyridin-2-yl as the optimal substituent on the imidazole ring to balance sstr3 activity and the hERG off-target liability. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.02.022

文献信息

• N-coating heterocyclic compounds
  申请人：——

  公开号：US20030176454A1

  公开（公告）日：2003-09-18

  A compound of the formula (I): wherein A is a hydrogen atom, an optionally substituted, unsaturated, N-containing heterocyclic group or a group of the formula (a): wherein R is an optionally substituted aryl group or an optionally substituted heterocyclic group; M is —(CH 2 )n-, —(CH 2 )n-O—(CH 2 )m-or —(CH 2 )n-NH—(CH 2 )m-, wherein n and m are independently 0, 1 or 2; Q is an optionally substituted cycloalkylene group, an optionally substituted arylene group or an optionally substituted divalent heterocyclic group; and the moiety of the formula (b): is an optionally substituted, unsaturated, mono-, di-, tri- or tetra-cyclic, N-containing heterocyclic group which may contain additional hetero atom(s) selected from the group consisting of nitrogen, oxygen and sulfur atoms as the ring member(s), its prodrug or a pharmaceutically acceptable salt thereof.

  公式(I)的化合物：其中A是氢原子，一个可选地取代的、不饱和的、含氮的杂环基团，或者公式(a)的基团：其中R是一个可选地取代的芳香族基团或者一个可选地取代的杂环基团；M是—(CH2)n-, —(CH2)n-O—(CH2)m-或—(CH2)n-NH—(CH2)m-，其中n和m各自为0、1或2；Q是一个可选地取代的环烷基烯基团、一个可选地取代的芳香族基团或者一个可选地取代的二价杂环基团；以及公式(b)的部分：是一个可选地取代的、不饱和的、单环、双环、三环或四环的、含氮的杂环基团，它可以包含作为环成员的额外杂原子，选自由氮、氧和硫原子组成的组，其前药或药用盐。
• An evaluation of Minor Groove Binders as anti-fungal and anti-mycobacterial therapeutics
  作者：Fraser J. Scott、Ryan J.O. Nichol、Abedawn I. Khalaf、Federica Giordani、Kirsten Gillingwater、Soumya Ramu、Alysha Elliott、Johannes Zuegg、Paula Duffy、Michael-Jon Rosslee、Lerato Hlaka、Santosh Kumar、Mumin Ozturk、Frank Brombacher、Michael Barrett、Reto Guler、Colin J. Suckling

  DOI：10.1016/j.ejmech.2017.05.039

  日期：2017.8

  details the synthesis and biological evaluation of a collection of 19 structurally related Minor Groove Binders (MGBs), derived from the natural product distamycin, which were designed to probe antifungal and antimycobacterial activity. From this initial set, we report several MGBs that are worth more detailed investigation and optimisation. MGB-4, MGB-317 and MGB-325 have promising MIC80s of 2, 4 and 0

  这项研究详细介绍了19种结构相关的次要凹槽粘合剂（MGB）的合成和生物学评估，这些粘合剂衍生自天然产物双歧霉素，旨在探测其抗真菌和抗分枝杆菌的活性。从这个初始设置开始，我们报告了几个MGB，值得进行更详细的调查和优化。MGB-4，MGB-317和MGB-325对真菌新孢子虫的MIC 80分别为2、4和0.25μg/ mL 。 MGB-353和MGB-354具有的MIC 99个小号3.1μM的针对结核分枝杆菌的结核分枝杆菌。这些化合物的选择性和活性与它们的物理化学性质和感染剂的细胞壁/膜特性有关。
• Selective <i>in vitro</i> anti-cancer activity of non-alkylating minor groove binders
  作者：Ryan J. O. Nichol、Abedawn I. Khalaf、Kartheek Sooda、Omar Hussain、Hollie B. S. Griffiths、Roger Phillips、Farideh A. Javid、Colin J. Suckling、Simon J. Allison、Fraser J. Scott

  DOI：10.1039/c9md00268e

  日期：——

  Finally, we present an initial investigation into the mechanism of action of one compound from this class, S-MGB-4, demonstrating that neither DNA double strand breaks nor the DNA damage stress sensor protein p53 are induced. This indicates that our S-MGBs are unlikely to act through an alkylating or DNA damage response mechanism.

  通过DNA烷基化机制发挥作用的传统细胞毒剂相对而言是非特异性的，导致治疗窗口较小，从而限制了其有效性。在这项研究中，我们评估24个非烷基化斯特拉斯克莱德小沟结合剂（S-MGBs），其中包括14个新型化合物，为一组在体外对人结肠癌细胞系的抗癌活性，顺铂敏感卵巢癌细胞系和耐顺铂的卵巢癌细胞系。人类非癌性视网膜上皮细胞系用于测量任何反应的选择性。我们已经鉴定出几种S-MGB，其活性与顺铂和卡铂相当，但体外具有更好的活性选择性指数，特别是S-MGB-4，S-MGB-74和S-MGB-317。此外，对顺铂耐药和顺铂敏感的卵巢癌细胞系的比较显示，我们的S-MGB与顺铂或卡铂没有交叉耐药性，并且它们可能具有不同的作用机制。最后，我们对这一类化合物S-MGB-4的作用机理进行了初步研究，表明既不诱导DNA双链断裂也不诱导DNA损伤应激传感器蛋白p53。这表明我们的S-MGB不太可能通过烷基化或DNA损伤反应机制起作用。
• [EN] N-CONTAINING HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLIQUES CONTENANT DE L'AZOTE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2001087845A2

  公开（公告）日：2001-11-22

  A compound of the formula (I): wherein A is a hydrogen atom, an optionally substituted, unsaturated, N-containing heterocyclic group or a group of the formula (a) : wherein R is an optionally substituted aryl group or an optionally substituted heterocyclic group;M is -(CH2)n-, -(CH2)n-O-(CH2)m- or -(CH2)n-NH-(CH2)m-, wherein n and m are independently 0,1 or 2; Q is an optionally substituted cycloalkylene group, an optionally substituted arylene group or an optionally substituted divalent heterocyclic group; andthe moiety of the formula (b): is an optionally substituted, unsaturated, mono-, di-, tri- or tetra-cyclic, N-containing heterocyclic group which may contain additional hetero atom(s) selected from the group consisting of nitrogen, oxygen and sulfur atoms as the ring member(s), its prodrug or a pharmaceutically acceptable salt thereof.
• SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists
  作者：Shuwen He、Peter H. Dobbelaar、Liangqin Guo、Zhixiong Ye、Jian Liu、Tianying Jian、Quang Truong、Shrenik K. Shah、Wu Du、Hongbo Qi、Raman K. Bakshi、Qingmei Hong、James D. Dellureficio、Edward Sherer、Alexander Pasternak、Zhe Feng、Mikhail Reibarkh、Melissa Lin、Koppara Samuel、Vijay B. Reddy、Stan Mitelman、Sharon X. Tong、Gary G. Chicchi、Kwei-Lan Tsao、Dorina Trusca、Margaret Wu、Qing Shao、Maria E. Trujillo、Guillermo Fernandez、Donald Nelson、Patricia Bunting、Janet Kerr、Patrick Fitzgerald、Pierre Morissette、Sylvia Volksdorf、George J. Eiermann、Cai Li、Bei B. Zhang、Andrew D. Howard、Yun-Ping Zhou、Ravi P. Nargund、William K. Hagmann

  DOI：10.1016/j.bmcl.2016.02.022

  日期：2016.3

  MK-4256, a tetrahydro-beta-carboline sstr3 antagonist, was discontinued due to a cardiovascular (CV) adverse effect observed in dogs. Additional investigations revealed that the CV liability (QTc prolongation) was caused by the hERG off-target activity of MK-4256 and was not due to sstr3 antagonism. In this Letter, we describe our extensive SAR effort at the C3 position of the tetrahydro-beta-carboline structure. This effort resulted in identification of 5-fluoro-pyridin-2-yl as the optimal substituent on the imidazole ring to balance sstr3 activity and the hERG off-target liability. (C) 2016 Elsevier Ltd. All rights reserved.